Research Topics
| Robert BastSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A genetically defined model for human ovarian cancerJinsong Liu
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 64:1655-63. 2004..These cells provide a novel model system to study human ovarian cancer...- Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancerGordon J S Rustin
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
Clin Cancer Res 10:3919-26. 2004 - Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapyLynn C Hartmann
Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
Clin Cancer Res 11:2149-55. 2005..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy... - Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancerZendra Lee
Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298, USA
Cancer Res 66:2740-8. 2006..The effect of serum on GROalpha production is also significantly decreased by siRNA inhibition of LPA(2) expression. These studies identify LPA as a primary regulator of GROalpha expression in ovarian cancer... 
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentDonna Badgwell
Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women s Oncology, Women s and Infants Hospital, Providence, RI 02905, USA
Gynecol Oncol 106:490-7. 2007..Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported in urine...- Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancerRobert C Bast
Department of Experimental Therapeutics and Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Discov 2:16-8. 2012..Inhibition of multiple signaling pathways will likely be required to achieve effective personalized therapy for patients whose cancers exhibit "PI3Kness.".. - Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkersRobert C Bast
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Int J Gynecol Cancer 22:S5-8. 2012..Both algorithms have high negative predictive values 94%-98%. Although a difference in specificity should not affect patient outcomes, it could affect distribution of medical resources... - Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapyIgnacio Romero
M D Anderson Cancer Center, Translational Research, Houston, Texas 77030, USA
Endocrinology 153:1593-602. 2012..Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents... - Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancerJohn J Kavanagh
Telik, Inc, Palo Alto, CA, USA
J Hematol Oncol 3:9. 2010..The primary endpoints were objective response rate (ORR) and progression-free survival (PFS)... - A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancerAhmed Ashour Ahmed
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 422, Houston, TX 77030, USA
Cancer Chemother Pharmacol 68:1033-44. 2011..To investigate the mechanistic basis of the anti-tumor effect of the compound ITB-301... - Correlation between CpG methylation profiles and hormone receptor status in breast cancersWeiwei Feng
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Breast Cancer Res 9:R57. 2007..The present study was undertaken to determine whether methylation of a set of growth-suppressor genes would correlate to the expression of estrogen receptors (ERs) and progesterone receptors (PRs)... - Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxelChun Fang Zou
Department of Gynecology, Obstetrics and Gynecology, Hospital of Fudan University, Shanghai 200011, PR China
BMC Cancer 11:22. 2011..The purpose of this study is to examine whether ARHI induces autophagy in breast cancer cells and to evaluate the effects of ARHI gene re-expression in combination with paclitaxel... - Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancersWeiwei Feng
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
BMC Cancer 10:378. 2010..This study is to investigate the status and role of methylation in lymph node metastatic tumors... - The biology of ovarian cancer: new opportunities for translationRobert C Bast
Departments of Experimental Therapeutics and Systems Biology, University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA
Nat Rev Cancer 9:415-28. 2009.... - New tumor markers: CA125 and beyondR C Bast
University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 15:274-81. 2005..In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer... - Translational crossroads for biomarkersRobert C Bast
University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:6103-8. 2005.... - Status of tumor markers in ovarian cancer screeningRobert C Bast
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 21:200s-205s. 2003..At present, screening women at conventional risk should be restricted to clinical trials. In the future, however, screening for ovarian cancer may reduce the morbidity and mortality of this disease... 
Modulating microtubule stability enhances the cytotoxic response of cancer cells to PaclitaxelAhmed Ashour Ahmed
Department of Experimental Therapeutics, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
Cancer Res 71:5806-17. 2011..Our results offer a functional classification of the genetic basis for paclitaxel sensitivity and they support the hypothesis that stabilizing microtubules prior to therapy could enhance antitumor responses to paclitaxel treatment...- Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylationWeiwei Feng
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 112:1489-502. 2008..Two imprinted genes, paternally expressed 3 (PEG3) and aplasia Ras homologue member I (ARHI), are the most frequently down-regulated in ovarian cancers on gene expression arrays... - In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancerMolly Brewer
Department of Gynecologic Oncology, University of Texas, The M D Anderson Cancer Center, Houston, TX 77030, USA
Gynecol Oncol 98:182-92. 2005..However, the effectiveness of its application for different populations has been questioned because of the genetic differences among normal, high risk, and women with cancer... - Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysisKaren H Lu
Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:3291-300. 2004..CONCLUSIONS: Our data are consistent with the possibility that a limited number of markers in combination might identify >99% of epithelial ovarian cancers despite the heterogeneity of the disease... - Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathwayJia-Ju Bao
Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 62:7264-72. 2002..Consequently, reexpression of ARHI in breast and ovarian cancer cells appears to induce apoptosis through a caspase-independent, calpain-dependent mechanism... - Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public WorkshopRobert C Bast
M D Anderson Cancer Center, Houston, TX, USA
Gynecol Oncol 107:173-6. 2007.... - Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalingXiao Feng Le
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 280:2092-104. 2005..Transcriptional regulation by anti-HER2 antibody through PI3K-AKT pathway may potentiate the growth inhibitory activity of docetaxel by affecting cell cycle progression... - Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancerZhen Lu
Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 12:2404-13. 2006..CONCLUSIONS: Taken together, our data suggest that ARHI expression is regulated at both the transcriptional and the posttranscriptional levels, contributing to the dramatic decrease in ARHI expression in ovarian cancers... - Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA
Cell Cycle 5:1654-61. 2006.... - Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expressionGong Yang
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA
J Biol Chem 279:4339-45. 2004..siRNA-mediated gene silencing of Her-2/neu and increasing the expression of thrombospondin-1 may be a useful therapeutic strategy for Her-2/neu-over-expressing breast or ovarian cancer... - Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancerJanos L Tanyi
Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:3534-45. 2003..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells... - Stanniocalcin 1 and ovarian tumorigenesisGuangzhi Liu
Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Natl Cancer Inst 102:812-27. 2010..Stanniocalcin 1 (STC1) is a secreted glycoprotein hormone. High expression of STC1 has been associated with several cancers including ovarian cancer, but its role in the development of ovarian cancer is not clear... - Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancersJiuhong Yuan
Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 63:4174-80. 2003..Other epigenetic modifications such as hypermethylation in CpG island III may also contribute to the loss of ARHI expression... - Potential markers that complement expression of CA125 in epithelial ovarian cancerDaniel G Rosen
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Gynecol Oncol 99:267-77. 2005..Several markers exhibited more intense expression in cancers than in normal organs. Further investigation is needed to demonstrate complementary expression of markers in serum... - Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survivalDaniel G Rosen
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:6559-66. 2004..CONCLUSIONS: Persistence of ARHI expression in epithelial ovarian cancers correlated with prolonged disease free survival and expression of the cyclin dependent kinase inhibitor p21(WAF1/CIP1)... - Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cellsXiao Feng Le
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Mol Cancer Ther 6:2843-57. 2007..The negative effects of cyclin G2 on cell cycle and cell proliferation, which occur without altering p27(Kip1) levels, may contribute to the ability of trastuzumab to inhibit breast cancer cell growth... - Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancerLin Wang
Departments of Experimental Therapeutics L W, R Z L, J Y, Z L, A N, R C B, Y Y, Clinical Cancer Prevention A H, S M L, and Pathology J L, A A S, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030
Clin Cancer Res 9:3660-6. 2003..This study investigated the relationship of ARHI expression to the progression of breast cancer... - Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2Xiao Feng Le
Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cell Cycle 7:3747-58. 2008..Similar mechanisms may contribute to the clinical anti-tumor activity of trastuzumab in combination with inhibitors of VEGF signaling pathway in women with breast cancers which overexpress HER2... - Early detection of ovarian cancerPartha M Das
University of Texas, MD Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX, USA
Biomark Med 2:291-303. 2008..In this review, we will assess the current status and describe future directions in ovarian cancer screening... - Dasatinib induces autophagic cell death in human ovarian cancerXiao Feng Le
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 116:4980-90. 2010..Dasatinib, an inhibitor of Src/Abl family kinases, can inhibit tumor growth of several solid tumors. However, the effect and mechanism of action of dasatinib in human ovarian cancer cells remains unknown... - Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancerDaniel G Rosen
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Methods Enzymol 407:660-76. 2006.... - Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 117:1661-9. 2011..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer... - Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cellsGong Yang
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 28:174-82. 2007.... - A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studiesVioleta G Hennessey
Department of Biostatistics, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 66:1275-83. 2010.... - Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironmentJingfang Zheng
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Cell Cycle 9:140-6. 2010.... - Prevention and early detection of ovarian cancer: mission impossible?Robert C Bast
M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Recent Results Cancer Res 174:91-100. 2007..In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer... - The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cellsZhen Lu
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Clin Invest 118:3917-29. 2008..Thus, ARHI can induce autophagic cell death, but can also promote tumor dormancy in the presence of factors that promote survival in the cancer microenvironment... - Project Zero Delay: a process for accelerating the activation of cancer clinical trialsRazelle Kurzrock
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
J Clin Oncol 27:4433-40. 2009..Eliminating administrative delays can accelerate the evaluation of new drugs without compromising patient safety or the quality of clinical research... - Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancersYinhua Yu
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Methods Enzymol 407:455-68. 2006..Growth of ovarian and breast cancer xenografts is reversibly suppressed by ARHI, but expression of the NTD mutant produced only a limited inhibitory effect on growth of xenografts... - Targeting Aurora kinases in ovarian cancerSiqing Fu
Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
Expert Opin Ther Targets 10:77-85. 2006..The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment... - Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancerDaniel G Rosen
Departments of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 11:632-7. 2005.... - HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathwaysXiao Feng Le
Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cell Cycle 4:87-95. 2005..The targets and pathways affected by trastuzumab work in concert to maximize the expression and inhibitory effect of p27Kip1, which leads to cell cycle G1 arrest and growth inhibition... - Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylationSatoshi Fujii
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Hum Mol Genet 12:1791-800. 2003.... - Overexpression of kallikrein 10 in epithelial ovarian carcinomasHyun S Shvartsman
Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
Gynecol Oncol 90:44-50. 2003..We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma... - ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancersRobert Z Luo
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
Oncogene 22:2897-909. 2003..Furthermore, unlike the Ras oncogene, ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers... - Epigenetic regulation of ARHI in breast and ovarian cancer cellsYinhua Yu
Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Ann N Y Acad Sci 983:268-77. 2003..Reactivation of both the silenced paternal and imprinted maternal alleles can be achieved by demethylation and inhibition of histone deacetylation... - A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cellsArata Nishimoto
Department of Experimental Therapeutics, Biochemistry and Molecular Biology, Immunology, and Molecular Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 65:6701-10. 2005.... - Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colonRebecca T Marquez
Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:6116-26. 2005..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble... - Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancersClaire F Verschraegen
Department of Gynecologic Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:845-52. 2003..The purpose of this study was to characterize cell cultures and xenografts derived from patients with ovarian cancer... - Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersYongkun Wei
Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Mol Carcinog 47:701-6. 2008..These results suggest that H3K27me3 expression is a prognostic indicator for clinical outcome in patients with breast, ovarian, and pancreatic cancers... - ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteinsShaoyi Huang
Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Biosci Rep 30:159-68. 2010..Thus ARHI-induced disruption of importin-binding to cargo proteins, including STAT3, could serve as an important regulatory mechanism that contributes to the tumour-suppressor function of ARHI... - MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouseYing Wang
Department of Molecular Genetics, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Differentiation 76:1081-92. 2008..These findings document the presence of MUC16 in murine ovarian cancer and in normal tissues and provide a foundation for future functional studies... - MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinomaAjoy K Samanta
Department of Biochemistry and Molecular Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 115:3897-908. 2009..The authors have demonstrated that MEKK3 plays a critical role in cytokine-mediated NFkappaB activation, and that stable expression of MEKK3 in cultured cells leads to increased NFkappaB activity... - Early detection of ovarian cancer: promise and realityRobert C Bast
Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology and Anatomic Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Cancer Treat Res 107:61-97. 2002 - Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaBAjoy K Samanta
Department of Biochemistry and Molecular Biology, Program in Genes and Development, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 279:7576-83. 2004..As such, MEKK3 may serve as a therapeutic target to control cancer cell resistance to cytokine- or drug-induced apoptosis... - Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancerGordon B Mills
Department of Molecular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 30:93-104. 2003..This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer... - The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosisDaniel G Rosen
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 107:2730-40. 2006..Further studies are needed to elucidate the mechanism of activation of Stat3, its effects on downstream targets, and its role in the neoplastic transformation of epithelial ovarian cells... - The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionXiao-Feng Le
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 278:23441-50. 2003..Regulation of the phosphorylation of p27Kip1 protein is one of the post-translational mechanisms by which anti-HER2 antibody upregulates the protein... - A novel hTERT promoter-driven E1A therapeutic for ovarian cancerXiaoming Xie
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, Houston, Texas 77030, USA
Mol Cancer Ther 8:2375-82. 2009..v. delivery of T-VISA-E1A:liposomal nanoparticles, suggesting a promising role of T-VISA-E1A for ovarian cancer treatment under a gene therapy setting... - Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancersJon R Wiener
Department of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Gynecol Oncol 88:73-9. 2003..The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers... - CA125/MUC16 is dispensable for mouse development and reproductionDong Joo Cheon
Program in Genes and Development, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA
PLoS ONE 4:e4675. 2009..These knockout mice provide a unique platform for future studies to identify the role of CA125/MUC16 in organ homeostasis and ovarian cancer... - Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancerLajos Pusztai
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
Cancer Invest 22:248-56. 2004..However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy... - Early detection of ovarian cancerDonna Badgwell
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Dis Markers 23:397-410. 2007..The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise... - Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agentsMolly Brewer
University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Biomed Opt 7:20-6. 2002..The objective of this study was to compare the effects of chemopreventive agents on natural fluorescence emission of ovarian cells in a cell culture and in a primate model as a feasibility trial to monitor drug activity... - The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesisGong Yang
Department of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 103:16472-7. 2006..Therefore, Gro-1 may be a therapeutic target as well as a diagnostic marker in ovarian cancer... - Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cellsXianjun Fang
Department of Molecular Therapeutics, M D Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 279:9653-61. 2004..These studies elucidate the transcriptional mechanism and the Edg LPA receptors involved in LPA-induced IL-6 and IL-8 production and suggest potential strategies to restrain the expression of these cytokines in ovarian cancer... - SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerAhmed Ashour Ahmed
Department of Experimental Therapeutics, M D Anderson Cancer Center, University of Texas, Houston, 77030, USA
Cancer Cell 18:109-21. 2010..Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers... - Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanismsMikihito Nakamori
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 9:2727-33. 2003..CONCLUSIONS: This newly generated fusogenic oncolytic HSV is a promising candidate for clinical testing against advanced ovarian cancer... - ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancerGershon Y Locker
American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
J Clin Oncol 24:5313-27. 2006..New markers and new evidence to support the use of the currently reviewed markers will be evaluated in future updates of these guidelines... - Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003 - Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer modelTravis Young
Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555 1031, USA
Oncogene 24:6174-84. 2005..This study demonstrates that functional proteomic analysis of a genetically defined cancer model provides a powerful approach toward systematically identifying cellular targets associated with oncogenic transformation... - Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancerUsha Menon
Department of Gynecological Oncology, Institute of Women's Health, University College London
J Clin Oncol 23:7919-26. 2005..It is being used in the United Kingdom Collaborative Trial of Ovarian Cancer Screening and in the United States in both the Cancer Genetics Network and the Gynecology Oncology Group trials of high-risk women... - Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueGary J Kelloff
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3881-4. 2004 - Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancerZhen Zhang
Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Cancer Res 64:5882-90. 2004..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer... - Individualized care for patients with cancer - a work in progressRobert C Bast
N Engl J Med 351:2865-7. 2004 - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerLyndsay Harris
Yale Cancer Center, Yale University, New Haven, CT, USA
J Clin Oncol 25:5287-312. 2007..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer... - Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributionsSteven J Skates
Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
J Clin Oncol 22:4059-66. 2004..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)... - The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massRichard G Moore
Women and Infants Hospital, Brown University, Providence, RI 02925, USA
Gynecol Oncol 108:402-8. 2008..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125... - Biomarkers and clinical trial designJohn Farley
Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
Gynecol Oncol 103:S3-5. 2006 - How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the aboveRichard G Moore
J Clin Oncol 25:4159-61. 2007 - Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancerZhen Zhang
Center for Biomarker Discovery, Department of Pathology, Johns Hopkins Medical Institutions, CRB II 3M04, 1550 Orleans Street, Baltimore, MD 21231, USA
Gynecol Oncol 107:526-31. 2007..In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers... - Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusRichard G Moore
Women and Infants Hospital, Brown University, Providence, RI 02925, USA
Gynecol Oncol 110:196-201. 2008..The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus...
Research Grants
- ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian CancerRobert Bast; Fiscal Year: 2009..These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible. ..
- UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERRobert Bast; Fiscal Year: 2007..Developmental research and career development programs have been strengthened and extended to other institutions. Perspective will continue to be provided by internal, external and advocate advisors. ..
- Paul Calabresi Clinical Oncology AwardRobert Bast; Fiscal Year: 2007..Each Calabresi scholar is guided by a clinical mentor and a translational mentor as well as the program's Advisory Committee, composed of experts in clinical, laboratory, and translational research. ..
- SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIESRobert Bast; Fiscal Year: 2004....
- ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian CancerRobert C Bast; Fiscal Year: 2010..These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible. ..